Peptide Schedule
5-Amino-1MQSmall moleculeNo amino acid sequence. Icon reflects category theme only.5-Amino-1MQ Dosage Calculator
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in fat cell metabolism and energy expenditure.
50mcg · Daily
Summary: Add 0mL BAC water to your 50mg vial. Draw to < 0.1 units on a U-100 syringe for a 50mcg dose. This vial will last 0 doses.
Cycle Planner
5-Amino-1MQ Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~4-6 hours (estimated oral)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
5-Amino-1MQ Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mg | Daily |
| Moderate | 100mg | Daily |
| Aggressive | 150mg | Daily |
Note: NNMT inhibitor taken orally in capsule form — not an injectable peptide. No human clinical trials exist. All dosing protocols are extrapolated from preclinical mouse data and community experience. Cycle 8-12 weeks on, 4-8 weeks off. Store capsules at room temperature in a cool, dry place.
About 5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in fat cell metabolism and energy expenditure. It's not technically a peptide — it's a quinolinium salt with a molecular weight of just 159.19 g/mol — but it's widely sold alongside peptides in the research compound market and commonly stacked with fat-loss peptides like AOD-9604 and tesofensine. NNMT was first identified as a therapeutic target for obesity in a landmark 2014 Nature study by Kraus et al., which showed that knocking down NNMT expression in white adipose tissue protected mice from diet-induced obesity by boosting cellular energy expenditure (PMID 24717514). The enzyme works by methylating nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor, and its expression is significantly elevated in the fat tissue and liver of obese individuals. When NNMT activity is high, it depletes both NAD+ precursors and SAM — two molecules the body needs for energy metabolism, DNA repair, and epigenetic regulation. 5-Amino-1MQ was developed by Neelakantan, McHardy, and colleagues at the University of Texas in 2017 as part of a structure-activity relationship study screening quinolinium-based NNMT inhibitors (PMID 28548833). It stood out for its selectivity: it doesn't inhibit related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway, making it a clean pharmacological tool for studying NNMT's role in metabolism. In a 2018 follow-up study, the same group demonstrated that subcutaneous administration of 5-Amino-1MQ to diet-induced obese mice significantly reduced body weight, white adipose tissue mass, and adipocyte size — without affecting food intake or causing observable adverse effects (PMID 29738706). A 2024 study further validated NNMT inhibition as a pharmacological approach, showing dose-dependent improvements in glucose tolerance, insulin sensitivity, and hepatic steatosis in DIO mice treated daily for 28 days (PMID 39161060). Despite these promising preclinical results, no human clinical trials have been conducted. All dosing recommendations circulating online are based on animal data and anecdotal reports from the peptide community.